{"id":573633,"date":"2021-11-09T12:22:01","date_gmt":"2021-11-09T12:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=573633"},"modified":"2021-11-09T12:22:01","modified_gmt":"2021-11-09T12:22:01","slug":"diabetic-peripheral-neuropathy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-peripheral-neuropathy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_573633.html","title":{"rendered":"Diabetic Peripheral Neuropathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"
\n
\"Diabetic<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cDiabetic Peripheral Neuropathy -Pipeline Insights, 2021,\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Diabetic Peripheral Neuropathy Pipeline Insight” <\/a><\/strong>report provides comprehensive insights about key companies and pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscapes. <\/p>\n

The report comprises Diabetic Peripheral Neuropathy pipeline <\/a><\/strong>drug profiles, including clinical and non-clinical stage products. It also includes the Diabetic Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Diabetic Peripheral Neuropathy pipeline products.    <\/p>\n

\"\" <\/p>\n

Diabetic Peripheral Neuropathy Overview<\/strong><\/p>\n

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the  symptoms and\/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of  other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there  are often motor features with advancing disease.<\/p>\n

It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability.<\/p>\n

Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report:<\/a><\/strong><\/p>\n